Adriamycin cardiotoxicity amelioration by alpha-tocopherol.
Adriamycin has become a potent member of the cancer chemotherapeutic program. However, the full utilization of adriamycin is limited by its cardiotoxicity. In experimental animals, alpha-tocopherol has been shown by some to ameliorate or prevent cardiac dysfunction without impairing antitumor effectiveness. During adriamycin therapy, future clinical research should consist of biochemical measurements of vitamin E in plasma, lipoperoxidation in red cells and platelets, while cars to indicate deficiency, should be considered as one method of ameliorating toxicity.
D000818:Animals; D002648:Child; D004317:Doxorubicin / Q000009:adverse effects*; D006321:Heart / Q000187:drug effects; D006331:Heart Diseases / Q000139:chemically induced* / Q000517:prevention & control; D006333:Heart Failure / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D051379:Mice; D009206:Myocardium / Q000473:pathology; D011817:Rabbits; D014810:Vitamin E / Q000494:pharmacology*
D014810:Vitamin E; D004317:Doxorubicin